Circulation, Preserved Ejection Fraction and Pulmonary

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension

Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study

Circulation

MARCH 16, 2025

Circulation, Volume 151, Issue 11 , Page e763-e763, March 18, 2025.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension

Letter by Dai et al Regarding Article, “Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction”

Circulation

MARCH 9, 2025

Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.

Preserved Ejection Fraction

Preserved Ejection Fraction Article Heart Failure Pulmonary

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

The Politics of HFpEF—What’s Good for the Left Is Good for the Right

JAMA Cardiology

JULY 23, 2024

Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Exercise

Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction

Circulation: Heart Failure

DECEMBER 18, 2023

Circulation: Heart Failure, Volume 16, Issue 12 , Page e010673, December 1, 2023. P=0.02) and with pulmonary wedge pressure but following different slopes at rest and during exercise (R2=0.49;P<0.001). mm Hg in HF with preserved ejection fraction patients and was also exacerbated by exercise. mm Hg and 1.2

Preserved Ejection Fraction

Preserved Ejection Fraction Exercise Cardiomyopathy Heart Failure

Trying to answer two casual queries on RV dysfunction

Dr. S. Venkatesan MD

AUGUST 3, 2024

However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. This may be correct when there is acute raise in RV after load, as in PE.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Heart Dysfunction

Abstract 4123391: CardioMEMS and Mavacamten: A Synergistic Approach in Managing Hypertrophic Obstructive Cardiomyopathy with HFpEF Phenotype

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4123391-A4123391, November 12, 2024. The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction

Preserved Ejection Fraction Cardiomyopathy Heart Failure Pulmonary

Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction

Circulation

DECEMBER 21, 2023

Circulation, Ahead of Print. BACKGROUND:Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities with HFpEF.

Preserved Ejection Fraction

Preserved Ejection Fraction Diet Heart Failure Exercise

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139791-A4139791, November 12, 2024. Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups.

Preserved Ejection Fraction

Preserved Ejection Fraction Hypertension Blood Pressure Obesity

Abstract 4143037: Prognostic Value of On-Treatment Left Ventricular Global Longitudinal Strain in Elderly Patients with Acute Heart Failure and Preserved Ejection Fraction

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4143037-A4143037, November 12, 2024. The study therefore investigated the prognostic role of GLS in the elder patients with ADHF and preserved left ventricular ejection fraction (LVEF).Methods:Patients, years, 50.6%

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Diabetes Pulmonary

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146852-A4146852, November 12, 2024. Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. 2022 were included.

Pulmonary

Pulmonary Hypertension Preserved Ejection Fraction Outcomes

Cardiovascular Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study

Letter by Dai et al Regarding Article, “Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction”

Webinars

The Politics of HFpEF—What’s Good for the Left Is Good for the Right

Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction

Trying to answer two casual queries on RV dysfunction

Abstract 4123391: CardioMEMS and Mavacamten: A Synergistic Approach in Managing Hypertrophic Obstructive Cardiomyopathy with HFpEF Phenotype

Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Abstract 4143037: Prognostic Value of On-Treatment Left Ventricular Global Longitudinal Strain in Elderly Patients with Acute Heart Failure and Preserved Ejection Fraction

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Stay Connected